Buserelin
Need Assistance?
  • US & Canada:
    +
  • UK: +

Buserelin

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). The drug's effects are dependent on the frequency and time course of administration. GnRH is released in a pulsatile fashion in the postpubertal adult. Initial interaction of any GnRH agonist, such as buserelin, with the GnRH receptor induces release of FSH and LH by gonadotrophes.

Category
Peptide Inhibitors
Catalog number
BAT-010025
CAS number
57982-77-1
Molecular Formula
C60H86N16O13
Molecular Weight
1239.42
Buserelin
IUPAC Name
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Synonyms
(Des-Gly10,D-Ser(tBu)6,Pro-NHEt9)-LHRH; Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-L-proline ethylamide; Bigonist; HOE-766; HOE766; HOE 766; Profact; Receptal; Suprecur; Suprefact; Tiloryth; Hoe-766 MP; D-Ser(tbu(sup 6))-LH-RH-(1-9)-nonapeptide ethylamide; (D-Ser(tbu)(sup 6)-EA(sup 10))-luteinizing hormone-releasing hormone
Related CAS
68630-75-1 (acetate)
Appearance
White to Off-white Solid
Purity
>98%
Density
1.43 g/cm3
Melting Point
186-188°C
Sequence
Pyr-HWSY-s(tBu)-LRP-NHEt
Storage
Store at 2-8°C under inert atmosphere
Solubility
Soluble in DMSO (Slightly), Methanol (Slightly), Water (Slightly)
InChI
InChI=1S/C60H86N16O13/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65)/t40-,41-,42-,43-,44-,45-,46-,47+,48-/m0/s1
InChI Key
CUWODFFVMXJOKD-UVLQAERKSA-N
Canonical SMILES
CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6
1.Long‑term follow‑up of buserelin‑induced enteric neuropathy in rats.
Jönsson A1, Sand E1, Ekblad E2, Ohlsson B1. Mol Med Rep. 2016 Apr;13(4):3507-13. doi: 10.3892/mmr.2016.4968. Epub 2016 Mar 3.
A few patients have been shown to develop severe abdominal pain and gastrointestinal dysmotility during treatment with gonadotropin‑releasing hormone (GnRH) analogs. A rat model of enteric neuropathy has been developed by administration of the GnRH analog buserelin to rats. Loss of enteric neurons and ganglioneuritis throughout the gastrointestinal tract has been described, without other histopathological changes. The aim of the present study was to investigate the long‑term effects of this rat model on body weight, and on morphology and inflammatory changes in the gastrointestinal tract. Rats were administered subcutaneous injections of buserelin or saline once daily for 5 days and allowed to recover for 3 weeks. This regimen was repeated four times. The rats were weighed weekly and were sacrificed 16 weeks after the fourth treatment. The bowel wall was measured by morphometry, and the presence of enteric neurons, mast cells, eosinophils and T‑lymphocytes was evaluated.
Online Inquiry
Verification code
Inquiry Basket